Reforgene passes intellectual property management system certification
Recently, Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") successfully passed the on-site audit certification of its intellectual property management system and obtained the "Intellectual Property Management System Certification", marking a new step for the company in the standardized management of intellectual property.
Passing the intellectual property management system certification is recognition of the company's intellectual property management work, covering the management of intellectual property related to the development of cell and gene medicines and their delivery technologies, and gene editing technologies.
As a leading innovative gene editing medicine enterprise, Reforgene has always adhered to independent innovation and attaches great importance to the creation, application, protection and management of intellectual property. We will take this as an opportunity to continue relying on our independent innovation R&D capability and intellectual property system advantages to provide strong support and guarantee for innovative development.
About the intellectual property management system
The certification of the intellectual property management system is mainly based on the Enterprise Intellectual Property Management Specification (GB/T29490-2013), which was formulated by the National Intellectual Property Administration and approved, promulgated and implemented by the General Administration of Quality Supervision, Inspection and Quarantine and the Standardization Administration of China. It is China's first national standard for enterprise intellectual property management. The specification aims to guide enterprises to establish a scientific, systematic and standardized intellectual property management system, effectively improving the contribution of intellectual property to enterprise operation and development.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.